News Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Market Closed - Nyse Other stock markets 04:00:02 2024-04-15 pm EDT			5-day change	1st Jan Change
300.4 ^USD	-0.01%		-7.94%	-6.96%

Apr. 11	Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	CI
Apr. 10	Bio-Rad Laboratories COO Andrew Last to Retire in September	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay	Apr. 11	AQ
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	Apr. 11	CI
Bio-Rad Laboratories COO Andrew Last to Retire in September	Apr. 10	MT
Bio-Rad’s Chief Operating Officer Andrew Last to Retire	Apr. 10	BU
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire	Apr. 10	CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating	Apr. 08	MT
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400	Apr. 03	MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center	Mar. 25	MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO	Mar. 20	MT
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer	Mar. 20	BU
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024	Mar. 20	CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024	Mar. 20	CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM	Feb. 29
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing	Feb. 29	MT
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day	Feb. 22	BU
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating	Feb. 16	MT
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating	Feb. 16	MT
Bio Rad Labs rises after posting upbeat fourth-quarter profit	Feb. 15	RE
Bio-Rad: Q4 Earnings Snapshot	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Summary

Filters